drugset / Trial / NCT05099510
Natrunix Safety PK Study in Healthy Volunteers
RandomizedSequentialOpen-labelTreatment
Summary
This trial will be a Phase I Open Label, Placebo-controlled Dose Escalation Study to Evaluate Safety and Pharmacokinetics of Natrunix via Subcutaneous Injection in Healthy Subjects. The target enrollment is 8 healthy subjects per cohort (including six for Natrunix and two for placebo). Three cohorts for a total of 24 healthy volunteers.
Timeline
- Start
- 2022-01-19
- Primary completion
- 2022-05-01
- Completion
- 2022-06-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | vilamakitug | Monoclonal antibody | 200 mg | Subcutaneous |
| Comparator | vilamakitug | Monoclonal antibody | 400 mg | Subcutaneous |
| Comparator | vilamakitug | Monoclonal antibody | 800 mg | Subcutaneous |
Indications
No indication recorded.